Horwich A, Peckham M J
Cancer Treat Rep. 1986 Nov;70(11):1329-31.
A total of 22 adults with metastatic nonseminomatous germ cell tumor of the testis and raised pretreatment serum levels of the beta subunit of human chorionic gonadotropin (HCG) had serial monitoring of serum HCG by weekly assay following initiation of chemotherapy with bleomycin, etoposide, and cisplatin (BEP). A transient rise in HCG (the marker "surge") was detected in 9 patients (41%), of whom one relapsed. None of the other 13 patients have relapsed (follow-up, 24-60 months), and the BEP regimen overall leads to an 83.3% disease-free survival (Br J Cancer 47:613-619, 1983). The marker surge is not an adverse prognostic factor during initial chemotherapy.
共有22例睾丸转移性非精原细胞瘤成年患者，其化疗前血清人绒毛膜促性腺激素（HCG）β亚基水平升高，在接受博来霉素、依托泊苷和顺铂（BEP）化疗后，通过每周检测对血清HCG进行连续监测。9例患者（41%）检测到HCG短暂升高（“激增”标志物），其中1例复发。其他13例患者均未复发（随访24 - 60个月），总体而言BEP方案导致无病生存率为83.3%（《英国癌症杂志》47:613 - 619, 1983）。在初始化疗期间，标志物激增并非不良预后因素。
